No Data
No Data
3sbio (01530.HK): The continuously rotating product flywheel is expected to drive the value to soar.
In the business field, there is a concept called the "flywheel effect", which refers to an enterprise finding a sustainable and virtuous cycle of business operation. For innovative drug companies, the rotation of this flywheel is clearly based on the continuous construction of high-quality innovative products. In other words, once the product flywheel of an innovative drug company starts to rotate, it can continuously generate new profit growth opportunities and achieve sustainable development. Among the many pharmaceutical companies, I believe that 3sbio (01530.HK) is a typical example of this. Recently, the company released its performance report for the first half of the year, showing sustained and steady performance. Let's take a closer look at what makes it unique.
3sbio (01530.HK) director and chairman Lou Jing increase shareholding by 0.26 million shares.
According to the latest equity disclosure information from the Hong Kong Stock Exchange, on August 23, 2024, 3sbio (01530.HK), the director and chairman, Lou Jing, increased his shareholding by 0.26 million shares at an average price of 5.7805 Hong Kong dollars per share, involving approximately 1.503 million Hong Kong dollars. After the increase, the latest number of shares held is 528,683,001 shares, and the shareholding ratio has increased from 21.86% to 21.88%.
Strong Growth and Diversified Portfolio Underpin Buy Rating for 3SBio
[Brokerage Focus] Guosen Securities maintains a "outperform" rating on 3sbio (01530), indicating that its research and development pipeline is about to enter the harvest period.
Golden Finance | Guosen Securities released a research report, stating that 3sbio (01530) achieved revenue of 4.389 billion yuan in the first half of 2024 (+16.0%), with a gross margin of 3.797 billion yuan (+18.6%), and the gross margin increased to 86.5% (+1.9pct); The company achieved a net income attributable to the parent of 1.09 billion yuan (+11.1%), and an adjusted operating net income attributable to the parent of 1.112 billion yuan (+1.5%). The business sectors such as biopharmaceuticals and hair health all achieved rapid growth. The bank pointed out that 3sbio has many pipelines in the fields of nephrology, blood tumors, self-immunity, hair and skin, etc.
3SBio Inc. (HKG:1530) Interim Results: Here's What Analysts Are Forecasting For This Year
3SBio: Balancing Growth Prospects With Financial Challenges – A Hold Rating by Sean Wu, CFA
No Data